1305 O'Brien Drive
About Pacific Biosciences
BUILT ON INNOVATION. DRIVEN BY DISCOVERY.
PacBio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. Our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. With a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
2019 Plant and Animal Sciences SMRT Grant Program
198 articles with Pacific Biosciences
Pacific Biosciences of California, Inc. announced financial results for its third quarter ended September 30, 2019..
Significant Investment to Accelerate Cancer Research Creates First Commercial Single Source for Combined FFPE Acquisition, FFPE RNA Isolation and Long-Read Sequencing
Pacific Biosciences of California, Inc. announced that more than 50 presentations will include data from the company’s Single Molecule, Real-Time sequencing platforms at next week’s American Society for Human Genetics 2019 annual meeting in Houston.
Phase Genomics’ Platform Links Viruses and Antibiotic Resistance Genes to the Microbiome in Study of a Highly Complex Microbial Community
New Study of Cow Rumen Finds Hundreds of New Viral and Antibiotic Resistance Hosts in Complex Microbiome Sample by Leveraging Proprietary Proximity Ligation Platform
The deal to acquire its rival, Pacific Biosciences, will provide Illumina with a more comprehensive sequencing test at a lower cost.
Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery
Brings Together Highly Accurate Short- and Long-Read Sequencing Technologies, Paving the Path to a More Perfect View of a Genome
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
The decision by the ITC is based on its interpretation that the term “single-molecule sequencing” is limited to sequencing-by-synthesis approaches, and that Oxford Nanopore’s sequencing approach is therefore not “single-molecule sequencing.”
Product, service and other revenue for the year ended December 31, 2017 increased by 19% to $93.5 million, compared to $78.6 million for 2016.
This will significantly expand the capacity for Single Molecule, Real-Time Sequencing for BGI’s global sequencing service business, which currently operates two Sequel Systems and a PacBio RS II Sequencing System.
Product, service and other revenue for the third quarter of 2017 increased by 9% to $23.5 million, compared to $21.5 million for the third quarter of 2016.
Ms. Ordonez brings more than thirty years of experience in the life sciences and diagnostics industries, with senior roles at Hoffmann-La Roche, Celera, Quest Diagnostics and RainDance Technologies.
PacBio's Recent Projects Highlight Success of SMRT Sequencing for Characterizing Structural Variation in Human Genomes
A series of publications and initiatives from the genomics community demonstrates the rapid adoption of Single Molecule, Real-Time Sequencing for discovering structural variants throughout the human genome
Pacific Biosciences And Bluebee Launch De Novo Genome Assembly Pipeline On The Bluebee Analysis Platform
Biophysics Study Makes Exciting Advancements For The Future Of DNA Sequencing, Pacific Biosciences Reveals
Novogene And Pacific Biosciences To Jointly Develop And Co-Market Novel Applications Based On Sequel Platform
Pacific Biosciences Technology Resolves Complex Maize Genome, Driving Demand For Other Large-Scale AgBio Sequencing Projects